First report of BCL-2 inhibitor TQB3909 in pts with relapsed or refractory non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML): Data from a phase I study

被引：1
|
作者：
Qi, J. [1 ]
Li, J. [2 ,9 ]
Xu, W. [2 ]
Zhao, X. [3 ]
Yin, Q. [4 ]
Li, Y. [5 ,6 ]
Xu, F. [7 ]
Huang, H. [8 ]
Li, J. [2 ,9 ]
Qian, W. [10 ]
Zhao, Q. [11 ]
Wang, J. [12 ]
机构：
[1] Chinese Acad Med Sci, Inst Hematol & Blood Dis Hosp, IGCP Ctr Stage Ward, Tianjin, Peoples R China
[2] Nanjing Med Univ, Dept Hematol, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Peoples R China
[3] Tianjin Peoples Hosp, Dept Hematol, Tianjin, Peoples R China
[4] Zhengzhou Univ, Dept Hematol, Henan Canc Hospital, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[5] Hunan Canc Hosp, Dept Lymphoma & Hemato, Changsha, Peoples R China
[6] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China
[7] Mianyang Cent Hosp, Dept Hematol, Mianyang, Peoples R China
[8] Sun Yat Sen Univ, Dept Gynecol Oncol, Canc Ctr, Guangzhou, Peoples R China
[9] Shandong Univ, Dept Hematol, Qilu Hosp, Jinan, Peoples R China
[10] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Med Sch, Hangzhou, Peoples R China
[11] CTTQ Chia Tai Tianqing Pharmaceut Grp Co Ltd, Nanjing Site, Clin Med, Nanjing, Peoples R China
[12] Chinese Acad Med Sci Peking Union Med Coll, Inst Hematol & Blood Hosp, Leukemia Ctr, Tianjin, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.851
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
800MO
引用
收藏
页码：S596 / S596
页数：1
相关论文
共 50 条
  • [1] A phase I dose-escalation study of ZN-d5, an BCL-2 inhibitor with improved selectivity, in patients with advanced non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML)
    Zaucha, J. M.
    Fiorino, T.
    Kalro, A.
    Shin, H-J.
    Viiala, N.
    Torres, L.
    Gordon, G.
    Kirshoff, R.
    Lopez, S.
    Makris, L.
    Miller, C.
    Park, S.
    Voliotis, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S617 - S617
  • [2] Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)
    Davids, Matthew Steven
    Seymour, John Francis
    Gerecitano, John F.
    Kahl, Brad S.
    Pagel, John M.
    Wierda, William G.
    Anderson, Mary Ann
    Darden, David E.
    Nolan, Cathy E.
    Gressick, Lori A.
    Yang, Jianning
    Chyla, Brenda J.
    Busman, Todd A.
    Graham, Alison M.
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Roberts, Andrew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    William, Basem M.
    Hohenstein, Maribeth
    Loberiza, Fausto R., Jr.
    Caponetti, Gabriel C.
    Bociek, R. Gregory
    Bierman, Philip
    Armitage, James O.
    Chan, Wing-Chung
    Vose, Julie M.
    BLOOD, 2010, 116 (21) : 131 - 131
  • [4] Clofarabine (CLO) is active in patients (pts) with refractory and/or relapsed non-Hodgkin's lymphoma (NHL): A phase I/II study
    Nabhan, Chadi
    Fried, Walter
    Galvez, Angel G.
    Venugopal, Parameswaran
    Gozun, Phillip
    Bitran, Jacob D.
    BLOOD, 2007, 110 (11) : 186B - 186B
  • [5] Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
    Salem, Ahmed Hamed
    Agarwal, Suresh K.
    Dunbar, Martin
    Enschede, Sari L. Heitner
    Humerickhouse, Rod A.
    Wong, Shekman L.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (04): : 484 - 492
  • [6] Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
    Davids, Matthew S.
    Roberts, Andrew W.
    Seymour, John F.
    Pagel, John M.
    Kahl, Brad S.
    Wierda, William G.
    Puvvada, Soham
    Kipps, Thomas J.
    Anderson, Mary Ann
    Salem, Ahmed Hamed
    Dunbar, Martin
    Zhu, Ming
    Peale, Franklin
    Ross, Jeremy A.
    Gressick, Lori
    Desai, Monali
    Kim, Su Young
    Verdugo, Maria
    Humerickhouse, Rod A.
    Gordon, Gary B.
    Gerecitano, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08) : 826 - 833
  • [7] Phase II clinical study of bortezomib (VELCADE®) in patients (pts) with relapsed refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).
    Strauss, SJ
    Maharaj, L
    Stec, J
    Boral, A
    Trehu, E
    Schenkein, D
    Joel, SP
    Lister, TA
    BLOOD, 2004, 104 (11) : 389A - 389A
  • [8] Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
    Moreno, V.
    Brana, I.
    Sepulveda Sanchez, J. M.
    Vieito Villar, M.
    Hernandez Guerrero, T.
    Doger, B.
    Saavedra, O.
    Pinto, A.
    Carlo Stella, C.
    Italiano, A.
    Michot, J-M.
    Musuraca, G.
    Sarmiento, R.
    De Alvaro, J.
    Zuraek, M.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Hanna, B.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2020, 31 : S5 - S5
  • [9] Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL).
    Goy, A
    Younes, A
    McLaughlin, P
    Pro, B
    Romaguera, J
    Hagemeister, F
    Fayad, L
    Trehu, EG
    Schenkein, D
    Rodriguez, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 577S - 577S
  • [10] Phase I and Pharmacokinetic (PK) Study of Everolimus (RAD001) in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL).
    Ogura, Michinori
    Uchida, Toshiki
    Maruyama, Dai
    Uike, Naokuni
    Choi, Ilseung
    Ishizawa, Kenichi
    Itoh, Kuniaki
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Shimada, Naomi
    Kobayashi, Ken
    Tobinai, Kensei
    BLOOD, 2009, 114 (22) : 682 - 683
12345